Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

J.J. Bissler; C. Kingswood; E. Radzikowska; B.A. Zonnenberg; M. Frost; E. Belousova; K. Budde

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Translated title of the contribution: Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

J.J. Bissler, C. Kingswood, E. Radzikowska, B.A. Zonnenberg, M. Frost, E. Belousova, K. Budde

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Original language	Undefined/Unknown
Pages (from-to)	817-824
Number of pages	8
Journal	The Lancet
Volume	9
Issue number	381
Publication status	Published - 2013

Access to Document

http://www.ncbi.nlm.nih.gov/pubmed/23312829

Cite this

Bissler, J. J., Kingswood, C., Radzikowska, E., Zonnenberg, B. A., Frost, M., Belousova, E., & Budde, K. (2013). Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet, 9(381), 817-824. http://www.ncbi.nlm.nih.gov/pubmed/23312829

@article{262219c482224fbbb2e63cf276ee7d3e,

title = "Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial",

author = "J.J. Bissler and C. Kingswood and E. Radzikowska and B.A. Zonnenberg and M. Frost and E. Belousova and K. Budde",

year = "2013",

language = "Undefined/Unknown",

volume = "9",

pages = "817--824",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "381",

}

Bissler, JJ, Kingswood, C, Radzikowska, E, Zonnenberg, BA, Frost, M, Belousova, E & Budde, K 2013, 'Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial', The Lancet, vol. 9, no. 381, pp. 817-824. <http://www.ncbi.nlm.nih.gov/pubmed/23312829>

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. / Bissler, J.J.; Kingswood, C.; Radzikowska, E. et al.
In: The Lancet, Vol. 9, No. 381, 2013, p. 817-824.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

AU - Bissler, J.J.

AU - Kingswood, C.

AU - Radzikowska, E.

AU - Zonnenberg, B.A.

AU - Frost, M.

AU - Belousova, E.

AU - Budde, K.

PY - 2013

Y1 - 2013

M3 - Article

SN - 0140-6736

VL - 9

SP - 817

EP - 824

JO - The Lancet

JF - The Lancet

IS - 381

ER -